The relative importance of common chemotherapy side effects has shifted substantially over the last few decades, according to a new study. In general, psychosocial effects have become more important while physical effects seem less significant to patients than in the past.
A new study identified simple risk factors that could help identify patients with extranodal marginal zone lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma) at high risk for poor outcomes.
Nearly one quarter of breast cancer patients with small, node-negative tumors have high-risk genomic characteristics and would likely benefit from chemotherapy, according to results of a new study presented at the 2017 ESMO Congress.
The combination of ramucirumab and docetaxel prolonged progression-free survival over chemotherapy alone in patients with platinum-refractory advanced urothelial carcinoma, the first time in this setting that a regimen has improved outcomes over chemotherapy.
A study comparing two options for follow-up protocol after complete lung cancer resection suggests that regular CT scans after resection may not be necessary, though there may be some benefits to these additional scans.
The advantage with pembrolizumab has continued to improve, offering significantly better overall survival than chemotherapy in patients with recurrent, advanced urothelial carcinoma, according to the mature results of a phase III trial.
The first head-to-head comparison of docetaxel and abiraterone acetate for high-risk prostate cancer patients starting long-term hormone therapy found benefit with both treatments when added to ADT. Treatment decisions may come down to specific toxicities, which differ between the treatments.
Weekly dose-dense chemotherapy can be delivered successfully and with lower toxicity than standard 3-weekly regimens, but it does not improve progression-free survival among patients with epithelial ovarian cancer, according to a large new study presented at the ESMO.
A new study including two separate cohorts found that male gender is a significant risk factor for mortality in patients with essential thrombocythemia. Gender may play a bigger role than thrombosis history in determining risk.